top of page
JPEG iPSC differentiated Myotubes (1).jp

MYOARETE

INNOVATIVE THERAPIES FOR TREATING ALL DMD PATIENTS

DISEASES
DISEASES

Duchenne Muscular Dystrophy (DMD) is a devastating genetic disease. Currently, there is no cure for DMD.  We at MyoArete are committed toward developing innovative therapies for treating all DMD patients. 

The MyoArete pipeline consists of utrophin upregulation-based products for treatments for DMD. These treatments are predicted to benefit all DMD patients, regardless of mutation.

 

PIPELINE

MyoArete is an innovative biopharmaceutical startup focused on developing cures for DMD. We use new platform technologies developed at the founder's laboratory at the University of Pennsylvania and exclusively licensed to MyoArete.

 

ABOUT US
contact

CONTACT US

Tejvir S. Khurana, MD, PhD. ,

Department of Physiology & Pennsylvania Muscle Institute,

Perelman School of Medicine, University of Pennsylvania,

750 Clinical Research Building (CRB),

415 Curie Boulevard,

Philadelphia, PA 19104-6085

Thanks for submitting!

Jeffrey A. James, Ph.D., CLP.

Associate Director, Perelman School of Medicine

Penn Center for Innovation

University of Pennsylvania

3600 Civic Center Boulevard

9th Floor

Philadelphia, PA 19104

Thanks for submitting!

bottom of page